Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Precision Medicine and Biomarkers

Clinical or translational studies aimed at optimally matching patients to treatments, including biomarkers and resistance mechanisms

SUBMIT TO JOURNAL
Latest in Precision Medicine and Biomarkers
May 25 2022
The vaginal microbiome is associated with endometrial cancer grade and histology
Hesamedin Hakimjavadi, Sophia H. George et al.
The human microbiome has been strongly correlated with disease pathology and outcomes, yet remains relatively underexplored in patients with malignant endometrial disease. In this study, vaginal microbiome samples were prospectively collected at the time of hysterectomy from 61 racially and ethnically diverse patients ...
May 06 2022
Development of an automated liquid biopsy assay for methylated markers in advanced breast cancer
Mary Jo Fackler, Suzana Tulac et al.
Current molecular liquid biopsy assays to detect recurrence or monitor response to treatment require sophisticated technology, highly trained personnel, and a turnaround time of weeks. We describe the development and technical validation of an automated Liquid Biopsy for Breast Cancer Methylation (LBx-BCM) prototype, a ...
May 04 2022
Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
Margaret L. Axelrod, Yu Wang et al.
Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. We used peripheral blood gene expression and cell-type abundance to identify biomarkers of response and recurrence in neoadjuvant chemotherapy–treated patients with breast cancer. We identified ...
April 26 2022
A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms
Qiujin Shen, Yahui Feng et al.
Although the concept of “myeloid neoplasm continuum” has long been proposed, few comparative genomics studies directly tested this hypothesis. Here we report a multi-modal data analysis of 730 consecutive newly diagnosed patients with primary myeloid neoplasm, along with 462 lymphoid neoplasm cases serving as the ...
March 21 2022
Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer
Teijo Pellinen, Kevin Sandeman et al.
Some clinically significant prostate cancers are missed by MRI. We asked whether the tumor stroma in surgically treated localized prostate cancer lesions positive or negative with MRI are different in their cellular and molecular properties, and whether the differences are reflected to the clinical course of the disease.
February 11 2022
Methylated Septin9 (mSEPT9): A Promising Blood-Based Biomarker for the Detection and Screening of Early-Onset Colorectal Cancer
Holli A. Loomans-Kropp, Yurong Song et al.
Early-onset colorectal cancer (EOCRC), defined as a diagnosis under age 50, is an emerging public health burden. As many of these individuals fall outside of screening guidelines, the development of a minimally invasive, accurate screening modality for this population is warranted. We evaluated the FDA-approved ...
January 20 2022
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation
Sophie Wildsmith, Jiabu Ye et al.
Programmed cell death ligand-1 (PD-L1), expressed on both tumor cells (TC) and tumor-associated immune cells (IC), has been shown to be a useful biomarker and predictive of response to anti-PD-L1 agents in certain tumor types. In recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), there is a growing ...
January 11 2022
A Randomized Clinical Trial of Precision Prevention Materials Incorporating MC1R Genetic Risk to Improve Skin Cancer Prevention Activities Among Hispanics
John Charles A. Lacson, Scarlet H. Doyle et al.
Skin cancer incidence is increasing among Hispanics, who experience worse outcomes than non-Hispanic Whites. Precision prevention incorporating genetic testing for (melanocortin-1 receptor) MC1R, a skin cancer susceptibility marker, may improve prevention behavior.
December 27 2021
Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics
Yang Gao, Elena B. Kabotyanski et al.
Polo-like kinase (PLK) family members play important roles in cell-cycle regulation. The founding member PLK1 is oncogenic and preclinically validated as a cancer therapeutic target. Paradoxically, frequent loss of chromosome 5q11–35, which includes PLK2, is observed in basal-like breast cancer. In this study, we found ...
December 08 2021
Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
Cynthia Villarreal-Garza, Ana S. Ferrigno et al.
The presence of BRCA pathogenic variants (PV) in triple-negative breast cancer (TNBC) is associated with a distinctive genomic profile that makes the tumor particularly susceptible to DNA-damaging treatments. However, patients with BRCA PVs can develop treatment resistance through the appearance of reversion mutations and ...
View all Precision Medicine and Biomarkers articles

Topics in Precision Medicine and Biomarkers

AACR Journals

 

 

  • Copyright © 2022 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept